Autologous T lymphocytes genetically modified to express T cell receptors or chimeric antigen receptors have shown great promise in the treatment of several cancers, including melanoma and leukemia. In addition to tumor-associated antigens and tumor-specific neoantigens, tumors expressing viral peptides can also be recognized by specific Tcells and are attractive targets for cell therapy. Hepatocellular carcinoma cells often have hepatitis B virus DNA integration and can be targeted by hepatitis B virus-specific T cells. Here, we describe a method to engineer hepatitis B virus-specific T cell receptors in primary human T lymphocytes based on electroporation of hepatitis B virus T cell receptor messenger RNA. This method can be extended to a large scale therapeutic T cell production following current good manufacturing practice compliance and is applicable to the redirection of T lymphocytes with T cell receptors of other virus specificities such as Epstein-Barr virus, cytomegalovirus, and chimeric receptors specific for other antigens expressed on cancer cells.
CITATION STYLE
Koh, S., Shimasaki, N., & Bertoletti, A. (2016). Redirecting T cell specificity using T cell receptor messenger RNA electroporation. In Methods in Molecular Biology (Vol. 1428, pp. 285–296). Humana Press Inc. https://doi.org/10.1007/978-1-4939-3625-0_19
Mendeley helps you to discover research relevant for your work.